Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Cancer 9, 457 (1 July 2009) | doi:10.1038/nrc2689
Therapeutics: Dependent on KRAS
Abstract
Although activating KRAS mutations occur frequently in cancer, targeting this oncogene has proved difficult. Three groups have now identified pathways that have not been previously linked to KRAS — all of which may provide pharmacologically tractable anticancer targets — and that are crucial in cancer cells dependent on activated KRAS.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
